VirTrial
DECEMBER 17, 2019
Clinical trials require a significant commitment from patients, particularly in regard to travel time to research sites for regular visits. Consider the additional patient burden involved in clinical trials for patients with paralysis, dementia, or other conditions that make travel difficult or impossible. Their immobility typically prevents them from participating in traditional on-site trials.
Drug Patent Watch
DECEMBER 16, 2019
DrugPatentWatch was used in a recent research study on branded drug sales following generic entry. In this paper, authors Jeffrey Fujimoto, Daniel M Tien, Sophie Snyder, Jeppe A Hertz, and…. The post The effect of patent expiration on sales of branded competitor drugs in a therapeutic class appeared first on DrugPatentWatch - Make Better Decisions.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
ECRG Media's Clinical Research Podcast
DECEMBER 20, 2019
Best Place To Live To Get Clinical Research Opportunities This episode we talk about which clinical research cities have the most opportunities. Where should you move if your going to move to a city in order to get a clinical research job. Don't forget to Subscribe for new content! Subscribe: [link] Call or Text: 910-502-3732 Email: eliteclinicalgroup@gmail.com Podcast: [link] Steemit: [link] Advertise: eliteclinicalgroup@gmail.com Watch: » Industry News: [link] » All Videos: [link] » Interview
Syneos Health
DECEMBER 20, 2019
Success in today’s commercial market environment demands that biopharmaceutical firms build profitable portfolios while establishing and demonstrating asset value earlier in the development life cyc
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Drug Discovery Today
DECEMBER 19, 2019
EIT Health will invest up to €2 million in two start-ups that offer the most effective and disruptive solutions to address either Women’s Health or Digital Therapeutics.Applications for the Wild Card programme are open until 9th February 2020.
Pharmacy Checkers
DECEMBER 20, 2019
The FDA has done something that prescription drug importation advocates had possibly given up on. Not me. The agency drafted a new proposed rule to allow importation from Canada of lower-cost drugs and industry guidance for drug manufacturers to import their FDA-approved foreign drug versions, for which they can charge lower prices. The proposed rule provides specifics so that states contemplating or already formulating wholesale drug importation programs have a shot at gaining approval for thos
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Drug Discovery Today
DECEMBER 18, 2019
Dr George Frodsham, CEO and founder of innovative MedTech company, MediSieve, has been selected as one of MIT Technology Review’s Innovators Under 35 Europe 2019.
Drug Discovery Today
DECEMBER 16, 2019
The topic of this month’s newsletter from Drug Discovery Today is “The Best of 2019”.
Drug Discovery Today
DECEMBER 16, 2019
Start Codon cohort companies to receive One Nucleus membership benefits
Drug Discovery Today
DECEMBER 16, 2019
Major learned societies initiate two-year strategic alliance
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Drug Discovery Today
DECEMBER 17, 2019
Somerset, N.J. & Birmingham, Ala.– December 10, 2019 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that it has completed clinical production of Bridge Therapeutics Inc.’s (Bridge) opioid addiction development therapeutic product, BT-219, and executed an Exclusive Licensing Agreement to use Catalent’s proprietary Zydis® orally disintegrating tab
Expert insights. Personalized for you.
98 
Let's personalize your content